Robert L Atmar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2389461/publications.pdf

Version: 2024-02-01

242	25,891	9234 74	7136 153
papers	citations	h-index	g-index

249	249	249	28760
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Remdesivir for the Treatment of Covid-19 â€" Final Report. New England Journal of Medicine, 2020, 383, 1813-1826.	13.9	5,834
2	Replication of human noroviruses in stem cellâ€"derived human enteroids. Science, 2016, 353, 1387-1393.	6.0	1,056
3	Norwalk Virus Shedding after Experimental Human Infection. Emerging Infectious Diseases, 2008, 14, 1553-1557.	2.0	608
4	Laboratory efforts to cultivate noroviruses. Journal of General Virology, 2004, 85, 79-87.	1.3	517
5	Immune Reconstitution Inflammatory Syndrome. Medicine (United States), 2002, 81, 213-227.	0.4	496
6	Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. PLoS ONE, 2012, 7, e35421.	1.1	485
7	Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. New England Journal of Medicine, 1999, 341, 1336-1343.	13.9	477
8	Norwalk Virus Infection and Disease Is Associated with ABO Histoâ€"Blood Group Type. Journal of Infectious Diseases, 2002, 185, 1335-1337.	1.9	429
9	Norovirus Vaccine against Experimental Human Norwalk Virus Illness. New England Journal of Medicine, 2011, 365, 2178-2187.	13.9	429
10	Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine, 2022, 386, 1046-1057.	13.9	418
11	Effects of Requiring prior Authorization for Selected Antimicrobials: Expenditures, Susceptibilities, and Clinical Outcomes. Clinical Infectious Diseases, 1997, 25, 230-239.	2.9	351
12	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 2022, 386, 1088-1091.	13.9	338
13	Diagnosis of Noncultivatable Gastroenteritis Viruses, the Human Caliciviruses. Clinical Microbiology Reviews, 2001, 14, 15-37.	5.7	333
14	Biopsy Neutrophilia, Neutrophil Chemokine and Receptor Gene Expression in Severe Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 968-975.	2.5	312
15	The Role of Immune Reconstitution Inflammatory Syndrome in AIDSâ€RelatedCryptococcus neoformansDisease in the Era of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2005, 40, 1049-1052.	2.9	309
16	Norovirus disease: changing epidemiology and host susceptibility factors. Trends in Microbiology, 2004, 12, 279-287.	3.5	284
17	Aichi Virus, Norovirus, Astrovirus, Enterovirus, and Rotavirus Involved in Clinical Cases from a French Oyster-Related Gastroenteritis Outbreak. Journal of Clinical Microbiology, 2008, 46, 4011-4017.	1.8	267
18	The Epidemiologic and Clinical Importance of Norovirus Infection. Gastroenterology Clinics of North America, 2006, 35, 275-290.	1.0	264

#	Article	IF	Citations
19	Clinical Responses to Undiluted and Diluted Smallpox Vaccine. New England Journal of Medicine, 2002, 346, 1265-1274.	13.9	263
20	Determination of the 50% Human Infectious Dose for Norwalk Virus. Journal of Infectious Diseases, 2014, 209, 1016-1022.	1.9	261
21	Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices â€" United States, 2020â€"21 Influenza Season. MMWR Recommendations and Reports, 2020, 69, 1-24.	26.7	258
22	Recovery of Drugâ€Resistant Influenza Virus from Immunocompromised Patients: A Case Series. Journal of Infectious Diseases, 2006, 193, 760-764.	1.9	253
23	Serological Correlate of Protection against Norovirusâ€Induced Gastroenteritis. Journal of Infectious Diseases, 2010, 202, 1212-1218.	1.9	233
24	Norwalk Virus-Like Particle Hemagglutination by Binding to H Histo-Blood Group Antigens. Journal of Virology, 2003, 77, 405-415.	1.5	230
25	Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. Journal of Infectious Diseases, 2015, 211, 870-878.	1.9	223
26	Norwalk Virusâ€"specific Binding to Oyster Digestive Tissues. Emerging Infectious Diseases, 2006, 12, 931-936.	2.0	218
27	Stem Cell-Derived Human Intestinal Organoids as an Infection Model for Rotaviruses. MBio, 2012, 3, e00159-12.	1.8	216
28	Antibody Correlates and Predictors of Immunity to Naturally Occurring Influenza in Humans and the Importance of Antibody to the Neuraminidase. Journal of Infectious Diseases, 2013, 207, 974-981.	1.9	203
29	Respiratory Tract Viral Infections in Inner-City Asthmatic Adults. Archives of Internal Medicine, 1998, 158, 2453.	4.3	194
30	Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine, 2003, 21, 3479-3482.	1.7	186
31	Detection and Quantification of Noroviruses in Shellfish. Applied and Environmental Microbiology, 2009, 75, 618-624.	1.4	183
32	Noroviruses everywhere: has something changed?. Current Opinion in Infectious Diseases, 2006, 19, 467-474.	1.3	182
33	Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation. Emerging Infectious Diseases, 2018, 24, 1453-1464.	2.0	179
34	Distribution of Norwalk Virus within Shellfish Following Bioaccumulation and Subsequent Depuration by Detection Using RT-PCR. Journal of Food Protection, 1998, 61, 1674-1680.	0.8	170
35	Common Emergence of Amantadineâ€•and Rimantadineâ€Resistant Influenza A Viruses in Symptomatic Immunocompromised Adults. Clinical Infectious Diseases, 1998, 26, 1418-1424.	2.9	160
36	Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons. Archives of Internal Medicine, 2006, 166, 1121.	4.3	156

#	Article	IF	Citations
37	Epidemiology of human noroviruses and updates on vaccine development. Current Opinion in Gastroenterology, 2014, 30, 25-33.	1.0	156
38	Respiratory viral infections in patients with chronic, obstructive pulmonary disease. Journal of Infection, 2005, 50, 322-330.	1.7	154
39	Transmission of viruses through shellfish: when specific ligands come into play. Current Opinion in Virology, 2012, 2, 103-110.	2.6	151
40	Development of Methods To Detect â€œNorwalk-Like Virusesâ€•(NLVs) and Hepatitis A Virus in Delicatessen Foods: Application to a Food-Borne NLV Outbreak. Applied and Environmental Microbiology, 2000, 66, 213-218.	1.4	148
41	Norwalk virus infection associates with secretor status genotyped from sera. Journal of Medical Virology, 2005, 77, 116-120.	2.5	148
42	Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice. Journal of Virology, 1998, 72, 1345-1353.	1.5	147
43	Host Transcriptional Response to Influenza and Other Acute Respiratory Viral Infections â€“ A Prospective Cohort Study. PLoS Pathogens, 2015, 11, e1004869.	2.1	147
44	Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After Introduction of Rotavirus Vaccination. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 57-60.	0.6	145
45	Norwalk Virus RNA Is Infectious in Mammalian Cells. Journal of Virology, 2007, 81, 12238-12248.	1.5	141
46	Noroviruses: The leading cause of gastroenteritis worldwide. Discovery Medicine, 2010, 10, 61-70.	0.5	141
47	Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations. Clinical Infectious Diseases, 2006, 43, 1135-1142.	2.9	140
48	Structural Analysis of Histo-Blood Group Antigen Binding Specificity in a Norovirus GII.4 Epidemic Variant: Implications for Epochal Evolution. Journal of Virology, 2011, 85, 8635-8645.	1.5	138
49	Portable 24-analyte surface plasmon resonance instruments for rapid, versatile biodetection. Biosensors and Bioelectronics, 2007, 22, 2268-2275.	5.3	135
50	Dual Respiratory Virus Infections. Clinical Infectious Diseases, 1997, 25, 1421-1429.	2.9	134
51	Life-Threatening Pseudomonas aeruginosa Infections in Patients with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 1992, 14, 403-411.	2.9	130
52	Distribution in Tissue and Seasonal Variation of Norovirus Genogroup I and II Ligands in Oysters. Applied and Environmental Microbiology, 2010, 76, 5621-5630.	1.4	128
53	Postacute COVID-19: An Overview and Approach to Classification. Open Forum Infectious Diseases, 2020, 7, ofaa509.	0.4	128
54	Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response. JAMA - Journal of the American Medical Association, 2015, 314, 237.	3.8	124

#	Article	IF	Citations
55	A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidateâ€"Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults. Journal of Infectious Diseases, 2014, 210, 1763-1771.	1.9	122
56	Influenza A virus outbreak in a neonatal intensive care unit. Pediatric Infectious Disease Journal, 1999, 18, 811-815.	1.1	122
57	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 1365-1376.	5.2	119
58	Immunopathogenesis of Respiratory Syncytial Virus Bronchiolitis. Journal of Infectious Diseases, 2007, 195, 1532-1540.	1.9	115
59	Strain-Dependent Norovirus Bioaccumulation in Oysters. Applied and Environmental Microbiology, 2011, 77, 3189-3196.	1.4	115
60	Serological Correlates of Protection against a GII.4 Norovirus. Vaccine Journal, 2015, 22, 923-929.	3.2	109
61	Noroviruses: State of the Art. Food and Environmental Virology, 2010, 2, 117-126.	1.5	108
62	Human noroviruses: recent advances in a 50-year history. Current Opinion in Infectious Diseases, 2018, 31, 422-432.	1.3	103
63	A semiquantitative approach to estimate Norwalk-like virus contamination of oysters implicated in an outbreak. International Journal of Food Microbiology, 2003, 87, 107-112.	2.1	101
64	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Reports Medicine, 2022, 3, 100679.	3.3	100
65	Replication and packaging of Norwalk virus RNA in cultured mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10327-10332.	3.3	99
66	A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine, 2010, 28, 2076-2079.	1.7	99
67	Widespread Outbreak of Norovirus Gastroenteritis among Evacuees of Hurricane Katrina Residing in a Large "Megashelter" in Houston, Texas: Lessons Learned for Prevention. Clinical Infectious Diseases, 2007, 44, 1032-1039.	2.9	97
68	Prospects and Challenges in the Development of a Norovirus Vaccine. Clinical Therapeutics, 2017, 39, 1537-1549.	1.1	95
69	Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. Journal of Allergy and Clinical Immunology, 2004, 113, 717-724.	1.5	93
70	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naÃ¯ve subjects. Vaccine, 2015, 33, 5225-5234.	1.7	92
71	Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021. MMWR Recommendations and Reports, 2021, 70, 1-16.	26.7	92
72	Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology, 2010, 406, 1-11.	1.1	88

#	Article	IF	Citations
73	Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recommendations and Reports, 2019, 68, 1-14.	26.7	87
74	Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients. Journal of General Virology, 2016, 97, 2291-2300.	1.3	85
75	Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges. Viruses, 2019, 11, 638.	1.5	84
76	Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. Journal of Infection, 2007, 54, 539-544.	1.7	83
77	Comparison of a New Neuraminidase Detection Assay with an Enzyme Immunoassay, Immunofluorescence, and Culture for Rapid Detection of Influenza A and B Viruses in Nasal Wash Specimens. Journal of Clinical Microbiology, 2000, 38, 1161-1165.	1.8	82
78	Mucosal and Cellular Immune Responses to Norwalk Virus. Journal of Infectious Diseases, 2015, 212, 397-405.	1.9	81
79	New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids. MSphere, 2021, 6, .	1.3	78
80	Comprehensive Analysis of a Norovirus-Associated Gastroenteritis Outbreak, from the Environment to the Consumer. Journal of Clinical Microbiology, 2010, 48, 915-920.	1.8	75
81	Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1700-1710.	3.3	75
82	Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. Journal of Infection, 2008, 57, 128-131.	1.7	74
83	Development of a Reverse Transcription-PCRâ€“DNA Enzyme Immunoassay for Detection of â€œNorwalk-Likeâ€•Viruses and Hepatitis A Virus in Stool and Shellfish. Applied and Environmental Microbiology, 2001, 67, 742-749.	1.4	72
84	Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2010, 125, 1369-1378.e2.	1.5	71
85	Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. Journal of Clinical Investigation, 2020, 130, 6194-6197.	3.9	71
86	Acute Respiratory Failure Associated with Cryptococcosis in Patients with AIDS: Analysis of Predictive Factors. Clinical Infectious Diseases, 1998, 27, 1231-1237.	2.9	70
87	Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine, 2012, 31, 190-195.	1.7	69
88	Lack of Norovirus Replication and Histo-Blood Group Antigen Expression in 3-Dimensional Intestinal Epithelial Cells. Emerging Infectious Diseases, 2013, 19, 431-438.	2.0	69
89	Genetic Manipulation of Human Intestinal Enteroids Demonstrates the Necessity of a Functional Fucosyltransferase 2 Gene for Secretor-Dependent Human Norovirus Infection. MBio, 2020, 11, .	1.8	65
90	Glycan recognition in globally dominant human rotaviruses. Nature Communications, 2018, 9, 2631.	5.8	63

#	Article	IF	Citations
91	Human norovirus exhibits strain-specific sensitivity to host interferon pathways in human intestinal enteroids. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23782-23793.	3.3	63
92	Adjuvants for Pandemic Influenza Vaccines. Current Topics in Microbiology and Immunology, 2009, 333, 323-344.	0.7	62
93	Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 888-899.	5.2	62
94	Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of IL-121This paper was presented at the First International Conference on Immunology and Aging, June 13â€“19, 1996, Bethesda, MD, USA.1. Mechanisms of Ageing and Development, 1997, 94, 25-39.	2.2	61
95	Use of Rotavirus Virus-Like Particles as Surrogates To Evaluate Virus Persistence in Shellfish. Applied and Environmental Microbiology, 2005, 71, 6049-6053.	1.4	61
96	Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeableHaemophilus influenzae. FEMS Immunology and Medical Microbiology, 2003, 37, 69-75.	2.7	60
97	Plasmid-based human norovirus reverse genetics system produces reporter-tagged progeny virus containing infectious genomic RNA. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4043-52.	3.3	60
98	Development of an immunomagnetic capture reverse transcription-PCR assay for the detection of Norwalk virus. Journal of Virological Methods, 2000, 90, 69-78.	1.0	59
99	Human Monoclonal Antibodies That Neutralize Pandemic GII.4ÂNoroviruses. Gastroenterology, 2018, 155, 1898-1907.	0.6	59
100	Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infectious Diseases, 2008, 8, 4.	1.3	58
101	Serum Hemagglutination Inhibition Activity Correlates with Protection from Gastroenteritis in Persons Infected with Norwalk Virus. Vaccine Journal, 2012, 19, 284-287.	3.2	56
102	Norovirus contamination on French marketed oysters. International Journal of Food Microbiology, 2013, 166, 244-248.	2.1	55
103	Intanza^{Â®}: a new intradermal vaccine for seasonal influenza. Expert Review of Vaccines, 2010, 9, 1399-1409.	2.0	53
104	Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine, 2009, 27, 5091-5095.	1.7	52
105	A doseâ€“response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine, 2007, 25, 5367-5373.	1.7	51
106	Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial. Journal of Infectious Diseases, 2016, 214, 845-853.	1.9	49
107	Norovirus vaccine development: next steps. Expert Review of Vaccines, 2012, 11, 1023-1025.	2.0	48
108	Noroviruses as a Cause of Diarrhea in Travelers to Guatemala, India, and Mexico. Journal of Clinical Microbiology, 2010, 48, 1673-1676.	1.8	47

#	Article	IF	Citations
109	Structural Analysis of Determinants of Histo-Blood Group Antigen Binding Specificity in Genogroup I Noroviruses. Journal of Virology, 2014, 88, 6168-6180.	1.5	47
110	Effects of Child and Maternal Histo-Blood Group Antigen Status on Symptomatic and Asymptomatic Enteric Infections in Early Childhood. Journal of Infectious Diseases, 2019, 220, 151-162.	1.9	47
111	Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in Humans. PLoS ONE, 2012, 7, e50830.	1.1	44
112	Shunting in cryptococcal meningitis. Journal of Neurosurgery, 2016, 125, 177-186.	0.9	44
113	Community Environmental Contamination of Toxigenic Clostridium difficile. Open Forum Infectious Diseases, 2017, 4, ofx018.	0.4	44
114	Correlates of Protection against Norovirus Infection and Diseaseâ€"Where Are We Now, Where Do We Go?. PLoS Pathogens, 2016, 12, e1005334.	2.1	44
115	Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine, 2015, 33, 568-576.	1.7	41
116	Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5830-E5837.	3.3	41
117	Infections in Hispanic Immigrants. Clinical Infectious Diseases, 2002, 34, 1627-1632.	2.9	40
118	Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine, 2009, 27, 5344-5348.	1.7	39
119	Bacteraemia in the elderly: predictors of outcome in an urban teaching hospital. Journal of Infection, 2005, 50, 288-295.	1.7	38
120	Environmental Detection of Genogroup I, II, and IV Noroviruses by Using a Generic Real-Time Reverse Transcription-PCR Assay. Applied and Environmental Microbiology, 2013, 79, 6585-6592.	1.4	38
121	In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infection Control and Hospital Epidemiology, 2015, 36, 1318-1323.	1.0	38
122	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recommendations and Reports, 2021, 70, 1-12.	26.7	37
123	Sensitive Detection of Norovirus Using Phage Nanoparticle Reporters in Lateral-Flow Assay. PLoS ONE, 2015, 10, e0126571.	1.1	37
124	Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine, 2001, 19, 4635-4643.	1.7	35
125	Antiviral targets of human noroviruses. Current Opinion in Virology, 2016, 18, 117-125.	2.6	35
126	Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response. Journal of Virology, 2016, 90, 8906-8923.	1.5	34

#	Article	IF	Citations
127	Comparison of Microneutralization and Histo-Blood Group Antigenâ€“Blocking Assays for Functional Norovirus Antibody Detection. Journal of Infectious Diseases, 2019, 221, 739-743.	1.9	34
128	Unanticipated Diagnoses Found at Autopsy in an Urban Public Teaching Hospital. American Journal of the Medical Sciences, 1996, 311, 215-220.	0.4	33
129	Vaccines for Pandemic Influenza: Summary of Recent Clinical Trials. Current Topics in Microbiology and Immunology, 2009, 333, 431-451.	0.7	32
130	Structural basis of glycan interaction in gastroenteric viral pathogens. Current Opinion in Virology, 2014, 7, 119-127.	2.6	32
131	Experimental Human Infection with Norwalk Virus Elicits a Surrogate Neutralizing Antibody Response with Cross-Genogroup Activity. Vaccine Journal, 2015, 22, 221-228.	3.2	32
132	Sequential Outbreaks of Infections by Distinct Acinetobacter baumannii Strains in a Public Teaching Hospital in Houston, Texas. Journal of Clinical Microbiology, 2008, 46, 198-205.	1.8	31
133	Tularemia vaccine: Safety, reactogenicity, â€œTakeâ€•skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain â€“ A phase 2 randomized clinical Trial. Vaccine, 2017, 35, 4730-4737.	1.7	30
134	Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine, 1990, 8, 217-224.	1.7	29
135	Seroepidemiology of Norovirusâ€Associated Travelers' Diarrhea. Journal of Travel Medicine, 2014, 21, 6-11.	1.4	28
136	Identification of human single-chain antibodies with broad reactivity for noroviruses. Protein Engineering, Design and Selection, 2014, 27, 339-349.	1.0	28
137	Characterization of Cross-Reactive Norovirus-Specific Monoclonal Antibodies. Vaccine Journal, 2015, 22, 160-167.	3.2	27
138	Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding. PLoS Pathogens, 2016, 12, e1005719.	2.1	27
139	Typing and subtyping clinical isolates of influenza virus using reverse transcription-polymerase chain reaction. Clinical and Diagnostic Virology, 1996, 7, 77-84.	1.8	26
140	Serological Responses to Experimental Norwalk Virus Infection Measured Using a Quantitative Duplex Time-Resolved Fluorescence Immunoassay. Vaccine Journal, 2011, 18, 1187-1190.	3.2	26
141	Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. Open Forum Infectious Diseases, 2019, 6, ofy352.	0.4	26
142	A Nosocomial Outbreak of Norovirus Infection Masquerading asClostridium difficileInfection. Clinical Infectious Diseases, 2009, 48, e75-e77.	2.9	25
143	Structural features of glycan recognition among viral pathogens. Current Opinion in Structural Biology, 2017, 44, 211-218.	2.6	25
144	Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey â€” Houston, Texas, 2017. Morbidity and Mortality Weekly Report, 2019, 68, 469-473.	9.0	24

#	Article	IF	Citations
145	A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine, 2010, 28, 3025-3029.	1.7	23
146	Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults. Clinical Infectious Diseases, 2012, 54, 311-317.	2.9	23
147	Editorial Commentary: Uncommon(ly Considered) Manifestations of Infection with Rhinovirus, Agent of the Common Cold. Clinical Infectious Diseases, 2005, 41, 266-267.	2.9	22
148	Antibody Responses to Norovirus Genogroup GI.1 and GII.4 Proteases in Volunteers Administered Norwalk Virus. Vaccine Journal, 2012, 19, 1980-1983.	3.2	22
149	Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination. Journal of Infectious Diseases, 2019, 220, 603-614.	1.9	22
150	Prevalence of hypervirulent Klebsiella pneumoniae-associated genes rmpA and magA in two tertiary hospitals in Houston, TX, USA. Journal of Medical Microbiology, 2016, 65, 1047-1048.	0.7	21
151	Dialysis Catheterâ€“related Bloodstream Infections in Patients Receiving Hemodialysis on an Emergency-only Basis: A Retrospective Cohort Analysis. Clinical Infectious Diseases, 2019, 68, 1011-1016.	2.9	21
152	Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes. Journal of Infectious Diseases, 2012, 206, 1069-1077.	1.9	20
153	Picornavirus, the Most Common Respiratory Virus Causing Infection among Patients of All Ages Hospitalized with Acute Respiratory Illness. Journal of Clinical Microbiology, 2012, 50, 506-508.	1.8	20
154	Secretory pathway antagonism by calicivirus homologues of Norwalk virus nonstructural protein p22 is restricted to noroviruses. Virology Journal, 2012, 9, 181.	1.4	20
155	Identification and Characterization of a Peptide Affinity Reagent for Detection of Noroviruses in Clinical Samples. Journal of Clinical Microbiology, 2013, 51, 1803-1808.	1.8	20
156	Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus). Veterinary Immunology and Immunopathology, 2013, 153, 308-311.	0.5	20
157	New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	20
158	Practical and Sensitive Screening Strategy for Detection of Influenza Virus. Journal of Clinical Microbiology, 2002, 40, 4353-4356.	1.8	19
159	Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Current Opinion in Pharmacology, 2007, 7, 484-490.	1.7	19
160	Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity. Nature Communications, 2022, 13, 1241.	5.8	19
161	Comparison of Trivalent Cold-Adapted Recombinant (CR) Influenza Virus Vaccine with Monovalent CR Vaccines in Healthy Unselected Adults. Journal of Infectious Diseases, 1995, 172, 253-257.	1.9	18
162	Norovirus in health care and implications for the immunocompromised host. Current Opinion in Infectious Diseases, 2019, 32, 348-355.	1.3	18

#	Article	IF	Citations
163	Use of Human Intestinal Enteroids to Evaluate Persistence of Infectious Human Norovirus in Seawater. Emerging Infectious Diseases, 2022, 28, 1475-1479.	2.0	18
164	Inactivated influenza vaccination for people with spinal cord injury. Archives of Physical Medicine and Rehabilitation, 2004, 85, 1886-1889.	0.5	17
165	Reducing the Dose of Smallpox Vaccine Reduces Vaccineâ€Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses. Journal of Infectious Diseases, 2007, 195, 826-832.	1.9	17
166	Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine, 2017, 35, 1675-1682.	1.7	17
167	B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. Vaccine Journal, 2017, 24, .	3.2	17
168	SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision. Open Forum Infectious Diseases, 2021, 8, ofab180.	0.4	16
169	Chapter 10 Viruses in Shellfish. Perspectives in Medical Virology, 2007, 17, 205-226.	0.1	15
170	Mapping Broadly Reactive Norovirus Genogroup I and II Monoclonal Antibodies. Vaccine Journal, 2015, 22, 168-177.	3.2	15
171	Glycan Recognition in Human Norovirus Infections. Viruses, 2021, 13, 2066.	1.5	15
172	Increasing Doses of an Inactivated Influenza A/H1N1 Vaccine Induce Increasing Levels of Crossâ€Reacting Antibody to Subsequent, Antigenically Different, Variants. Journal of Infectious Diseases, 2008, 198, 1016-1018.	1.9	13
173	An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults. Journal of Infectious Diseases, 2019, 219, 410-414.	1.9	13
174	Rotavirus VLP2/6: a new tool for tracking rotavirus in the marine environment. Research in Microbiology, 2004, 155, 575-578.	1.0	12
175	Human Norovirus Histo-Blood Group Antigen (HBGA) Binding Sites Mediate the Virus Specific Interactions with Lettuce Carbohydrates. Viruses, 2019, 11, 833.	1.5	12
176	Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine, 2011, 29, 8066-8072.	1.7	11
177	Norovirus Antigen Detection with a Combination of Monoclonal and Single-Chain Antibodies. Journal of Clinical Microbiology, 2015, 53, 3916-3918.	1.8	11
178	Flotation Immunoassay: Masking the Signal from Free Reporters in Sandwich Immunoassays. Scientific Reports, 2016, 6, 24297.	1.6	11
179	Engineering Specificity from Broad to Narrow: Design of a Î²-Lactamase Inhibitory Protein (BLIP) Variant That Exclusively Binds and Detects KPC Î²-Lactamase. ACS Infectious Diseases, 2016, 2, 969-979.	1.8	10
180	High-Resolution Mapping of Human Norovirus Antigens via Genomic Phage Display Library Selections and Deep Sequencing. Journal of Virology, 2020, 95, .	1.5	10

#	Article	IF	Citations
181	Histo-blood group antigens of glycosphingolipids predict susceptibility of human intestinal enteroids to norovirus infection. Journal of Biological Chemistry, 2020, 295, 15974-15987.	1.6	10
182	Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. Journal of Infectious Diseases, 2021, 224, 1372-1382.	1.9	10
183	Detection of Human Caliciviruses in Fecal Samples by RT-PCR. Methods in Molecular Biology, 2010, 665, 39-50.	0.4	10
184	Binding and Inactivation of Viruses on and in Food, with a Focus on the Role of the Matrix. , 0, , 189-208.		10
185	Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. Vaccine Journal, 2016, 23, 181-183.	3.2	9
186	Deep sequencing of phage-displayed peptide libraries reveals sequence motif that detects norovirus. Protein Engineering, Design and Selection, 2017, 30, 129-139.	1.0	9
187	â€˜String Testâ€™ for Hypermucoviscous Klebsiella pneumoniae. American Journal of Medicine, 2021, 134, e520-e521.	0.6	9
188	Antiviral Activity of Olanexidine-Containing Hand Rub against Human Noroviruses. MBio, 2022, 13, e0284821.	1.8	9
189	Development of a Gaussia Luciferase-Based Human Norovirus Protease Reporter System: Cell Type-Specific Profile of Norwalk Virus Protease Precursors and Evaluation of Inhibitors. Journal of Virology, 2014, 88, 10312-10326.	1.5	8
190	Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. Journal of Virology, 2017, 91, .	1.5	8
191	Correspondence on â€˜Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohortâ€™. Annals of the Rheumatic Diseases, 2022, 81, e239-e239.	0.5	8
192	Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations â€” United States, 2021. Morbidity and Mortality Weekly Report, 2022, 71, 290-292.	9.0	8
193	Bile Goes Viral. Viruses, 2021, 13, 998.	1.5	7
194	Immunological Detection and Characterization. , 2014, , 47-62.		7
195	Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine, 2019, 37, 2561-2568.	1.7	6
196	Active Surveillance for Norovirus in a US Veterans Affairs Patient Population, Houston, Texas, 2015â€“2016. Open Forum Infectious Diseases, 2019, 6, ofz115.	0.4	6
197	Norovirus in Cancer Patients: A Review. Open Forum Infectious Diseases, 2021, 8, ofab126.	0.4	6
198	Identification and Characterization of Single-Chain Antibodies that Specifically Bind GI Noroviruses. PLoS ONE, 2017, 12, e0170162.	1.1	6

#	Article	IF	Citations
199	Effects of infection and disease with Mycobacterium tuberculosison serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen. BMC Infectious Diseases, 2013, 13, 276.	1.3	5
200	Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?. Journal of Infectious Diseases, 2016, 213, 1211-1213.	1.9	5
201	Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. Journal of Infectious Diseases, 2021, 224, 1712-1719.	1.9	5
202	Influenza vaccine in patients with asthma. Expert Review of Vaccines, 2006, 5, 111-118.	2.0	4
203	Molecular Methods of Virus Detection in Foods. , 2006, , 121-149.		4
204	Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine, 2016, 34, 547-554.	1.7	4
205	Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine, 2019, 37, 5161-5170.	1.7	4
206	Searching for Improved Flu Vaccinesâ€"The Time Is Now. Journal of Infectious Diseases, 2019, 221, 1-4.	1.9	4
207	An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 3138-3145.	1.4	4
208	Case-based audit and feedback around a decision aid improved antibiotic choice and duration for uncomplicated cystitis in primary care clinics. Family Medicine and Community Health, 2021, 9, e000834.	0.6	4
209	Chlamydia species and Mycoplasma pneumoniae. Current Infectious Disease Reports, 1999, 1, 73-79.	1.3	3
210	Prevalence and control of Norovirus and hepatitis A virus in shellfish. Food Safety Assurance and Veterinary Public Health, 2013, , 137-168.	0.4	3
211	Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009â€"2010 seasonal trivalent influenza vaccinations. Vaccine, 2015, 33, 163-173.	1.7	3
212	Norovirus Protease Structure and Antivirals Development. Viruses, 2021, 13, 2069.	1.5	3
213	Viral Pathogens of the Intestine. , 0, , 525-545.		3
214	Infections Associated with the Consumption of Goat Cheese. Journal of Travel Medicine, 1995, 2, 178-181.	1.4	2
215	Nonculturable agents of viral gastroenteritis. Clinical Microbiology Newsletter, 1997, 19, 177-182.	0.4	2
216	Helium beam shadowing for high spatial resolution patterning of antibodies on microstructured diagnostic surfaces. Biointerphases, 2013, 8, 9.	0.6	2

#	Article	IF	Citations
217	Reply to Kirby et al. Journal of Infectious Diseases, 2015, 211, 167-167.	1.9	2
218	Birth Cohort Studies: Toward Understanding Protective Immunity to Human Noroviruses. Clinical Infectious Diseases, 2021, 72, 230-232.	2.9	2
219	Enforcing antimicrobial restrictions. American Journal of Health-System Pharmacy, 1996, 53, 796-797.	0.5	1
220	Creating an Outpatient-Specific Antibiogram to Guide Treatment for Urinary Tract Infections. Infection Control and Hospital Epidemiology, 2020, 41, s182-s183.	1.0	1
221	1098. Norovirus Infection in Cancer Patients Undergoing Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T). Open Forum Infectious Diseases, 2020, 7, S578-S579.	0.4	1
222	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infectious Diseases, 0, , .	0.4	1
223	Proteomic Analysis Of Bronchoalveolar Lavage Of Patients With COPD And COPD Exacerbations. , 2010, , .		0
224	606Noroviruses (NoVs) as a Cause of Diarrhea in Immunocompromised Pediatric Transplant Recipients. Open Forum Infectious Diseases, 2014, 1, S27-S28.	0.4	0
225	Acute Gastroenteritis Viruses. , 2015, , 1083-1103.		0
226	Human Caliciviruses. , 2016, , 1189-1208.		0
227	Active Surveillance to Quantify the Burden of Norovirus in a U.S. Veterans Affairs (VA) Patient Population, Houston, 2015â€“2016. Open Forum Infectious Diseases, 2017, 4, S317-S317.	0.4	0
228	Immune Response. , 2017, , 89-106.		0
229	2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients. Open Forum Infectious Diseases, 2018, 5, S748-S748.	0.4	0
230	652. What Is Blood Got to Do with It? Genetic Susceptibility to Norovirus and Rotavirus Infection: Results From the SUPERNOVA Network. Open Forum Infectious Diseases, 2018, 5, S236-S237.	0.4	0
231	2650. Evaluating Antiviral Agents for Human Noroviruses Using a Human Intestinal Enteroid Model. Open Forum Infectious Diseases, 2019, 6, S927-S928.	0.4	0
232	Influenza Vaccines After 7 Decades: Still on the Learning Curve. Journal of Infectious Diseases, 2019, 220, 1240-1242.	1.9	0
233	Improving Influenza Prevention: Modest Changes With Large Effects. Clinical Infectious Diseases, 2020, 70, 2503-2504.	2.9	0
234	Influenza Challenge Models: Ready for Prime Time?. Clinical Infectious Diseases, 2020, 71, 3012-3013.	2.9	0

#	Article	IF	Citations
235	Immune Response to Influenza Vaccine in Adult HCV Patients Receiving Peginterferon and Ribavirin Therapy. American Journal of Gastroenterology, 2005, 100, S128.	0.2	0
236	RHINOVIRUSES. , 2009, , 2170-2193.		0
237	Respiratory Virus Infections. Infectious Disease and Therapy, 2010, , 246-271.	0.0	0
238	Gastrointestinal Tract Infections. Infectious Disease and Therapy, 2010, , 272-284.	0.0	0
239	Calicivirus Infections. , 2011, , 411-415.		0
240	1122. Improving Knowledge of Infectious Disease Fellows Regarding Infection Prevention & Antibiotic Stewardship Using a Multi-Faceted Approach. Open Forum Infectious Diseases, 2020, 7, S591-S591.	0.4	0
241	Association of secretor status and recent norovirus infection with gut microbiome diversity metrics in a Veterans Affairs population. Open Forum Infectious Diseases, 2022, 9, ofac125.	0.4	0
242	700. Risk Factors and Molecular Epidemiology of Acute and Chronic Norovirus Infection at a Large Tertiary Care Cancer Center. Open Forum Infectious Diseases, 2021, 8, S450-S451.	0.4	0